Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

被引:6
|
作者
Johns, Andrew C. [1 ]
Yang, Mike [2 ]
Wei, Lai [3 ]
Grogan, Madison [4 ]
Spakowicz, Daniel [3 ,4 ]
Patel, Sandipkumar H. [4 ]
Li, Mingjia [5 ]
Husain, Marium [4 ]
Kendra, Kari L. [4 ]
Otterson, Gregory A. [4 ]
Rosko, Ashley E. [6 ]
Andersen, Barbara L. [7 ]
Carbone, David P. [4 ]
Owen, Dwight H. [4 ]
Presley, Carolyn J. [4 ,8 ]
机构
[1] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Internal Med, Div Med Oncol, Comprehens Canc Ctr, Columbus, OH 43210 USA
[5] Ohio State Univ, Div Hosp Med, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[6] Ohio State Univ, Dept Internal Med, Div Hematol, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA
[8] Ohio State Univ, James Canc Hosp & Solove Res Inst, Comprehens Canc Ctr, 13th Floor Lincoln Tower, 1800 Cannon Dr, Columbus, OH 43210 USA
来源
ONCOLOGIST | 2023年
基金
美国国家卫生研究院;
关键词
checkpoint inhibitor; immunotherapy; toxicity; geriatrics; immune-related adverse events; CHEMOTHERAPY TOXICITY; DEPRESSION; MANAGEMENT; SURVIVAL;
D O I
10.1093/oncolo/oyad097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibitor immunotherapy is revolutionizing cancer care but can lead to significant toxicity. This article describes potential risk factors for immune-related adverse events among older adults. Objectives Immune checkpoint inhibitor immunotherapy (IO) is revolutionizing cancer care but can lead to significant toxicity. This study seeks to describe potential risk factors for immune-related adverse events (irAEs) specifically among older adults. Materials and Methods This was a retrospective study at a single academic comprehensive cancer center based on chart review data abstracted by physicians. For patients aged >= 70 years, frequency, type, and grade of irAEs and their association with baseline patient demographics, comorbidities, mobility, and functional status were characterized using bivariate analysis. Based on those results, multivariable logistic regressions were constructed to model the association between these characteristics with any grade and grade 3 or higher irAEs. Results Data were analyzed for 238 patients aged >= 70 years who received IO for mostly (>= 90%) advanced cancer between 2011 and 2018. Thirty-nine percent of older adults experienced an irAE and 13% experienced one that was grade 3 or higher. In the multivariable analysis, depression was associated with an increased incidence of any grade irAE, while decreased life-space mobility was associated with an increased incidence of grade >= 3 irAEs. Conclusion Most characteristics of special interest among older adults, include fall risk, weight loss, cognitive limitations, and hearing loss, were not associated with irAEs in our study. However, decreased life-space mobility and depression are potential risk factors for IO toxicity among older adults with advanced cancer. Interventions designed to evaluate and mitigate modifiable risk factors for treatment-related toxicity are needed, and the results of this study may be useful for guiding those efforts.
引用
收藏
页码:E625 / E632
页数:8
相关论文
共 50 条
  • [41] Checkpoint inhibitor immunotherapy in kidney cancer
    Wenxin Xu
    Michael B. Atkins
    David F. McDermott
    Nature Reviews Urology, 2020, 17 : 137 - 150
  • [42] Checkpoint inhibitor immunotherapy in kidney cancer
    Xu, Wenxin
    Atkins, Michael B.
    McDermott, David F.
    NATURE REVIEWS UROLOGY, 2020, 17 (03) : 137 - 150
  • [43] Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy
    Vigano, Marialuisa
    Wang, Lixing
    As'sadiq, Alia
    Samarani, Suzanne
    Ahmad, Ali
    Costiniuk, Cecilia T.
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [44] Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy
    Shemonti Hasan
    Onilia Zorio
    B. Mark Keegan
    Brian G. Weinshenker
    Eoin P. Flanagan
    W. Oliver Tobin
    Orhun H. Kantarci
    Michel Toledano
    Sean J. Pittock
    Sebastian Lopez-Chiriboga
    Anastasia Zekeridou
    Cristina Valencia-Sanchez
    Journal of Neurology, 2023, 270 : 4707 - 4712
  • [45] Incidence and risk factors of immune checkpoint inhibitor-induced colitis in Korean patients with cancer
    Kim, Tae Kyun
    Lee, Hyun Seok
    Kim, Eun Soo
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2025, 40 (01): : 49 - 56
  • [46] The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
    Mpakali, Anastasia
    Stratikos, Efstratios
    CANCERS, 2021, 13 (01) : 1 - 30
  • [47] Gut microbes modulate host response to immune checkpoint inhibitor cancer immunotherapy
    Liu, Kebin
    Lu, Chunwan
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S608 - S610
  • [48] Risk Factors and Prognostic Analysis of Immune Checkpoint Inhibitor-Related Colitis in Lung Cancer
    Wang, Shiyang
    Tian, Binhe
    Wang, Hanping
    JOURNAL OF INFLAMMATION RESEARCH, 2024, 17
  • [49] Investigating Risk Factors for Immune Checkpoint Inhibitor-induced Pneumonitis in Lung Cancer Patients
    Zhou, C.
    Rose, M. L.
    Afzal, M.
    Russo, G. A.
    Shirai, K.
    Feller-Kopman, D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [50] Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy
    Hasan, Shemonti
    Zorio, Onilia
    Keegan, B. Mark
    Weinshenker, Brian G. G.
    Flanagan, Eoin P. P.
    Tobin, W. Oliver
    Kantarci, Orhun H. H.
    Toledano, Michel
    Pittock, Sean J. J.
    Lopez-Chiriboga, Sebastian
    Zekeridou, Anastasia
    Valencia-Sanchez, Cristina
    JOURNAL OF NEUROLOGY, 2023, 270 (10) : 4707 - 4712